Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats

International Journal of Artificial Organs

Volumn 28, Issue 2, 2005, Pages 170-176

  Duman, Soner ^a   Sen, S ^a   Sozmen E Y ^a   Oreopoulos, D G ^b  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atorvastatin; Peritoneal sclerosis; Statins; TGF 1; VEGF

Indexed keywords

DIALYSIS; EFFLUENTS; GLUCOSE; METABOLISM; POTABLE WATER; PROTEINS; RATS; ULTRAFILTRATION;

ANTI-INFLAMMATORIES; ATORVASTATIN; DIALYSATES; INFLAMMATORY PROPERTIES; PERITONEAL DIALYSIS; PERITONEAL SCLEROSE; STATINS; TGF-Β; TGF-Β1; VEGF;

UREA;

ATORVASTATIN; DIANEAL; DRINKING WATER; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERTONIC SOLUTION; PERITONEAL DIALYSIS FLUID; TRANSFORMING GROWTH FACTOR BETA1; UREA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIALYSATE; EFFLUENT; EXPOSURE; GLUCOSE ABSORPTION; MALE; MEMBRANE TRANSPORT; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PROTECTION; RAT; SCLEROSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THICKNESS; ULTRAFILTRATION; UREA BLOOD LEVEL;

EID: 16844380844     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502800214     Document Type: Article

References (38)

1. Selgas R, Fernandez-Reyes M-J, Bosque E, Bajo M-A, Borrego F, Jimenez C, Del Peso G, De Alvaro F. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective median long-term study. Am J Kidney Dis 1994; 23: 64-73.
2. Di Paolo N, Garosi G. Peritoneal sclerosis. J Nephrol 1999; 12: 347-61.
3. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, Grabensee B. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int 2001; 78 (suppl): S42-7.
4. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996 72: 171-6.
5. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102.
6. Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, Gauldie J. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160: 2285-94.
7. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-41.
8. Chaimovitz C. Peritoneal dialysis. Kidney Int 1994; 45: 1226-40.
9. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
10. Border WA, Noble NA. TGF β in kidney fibrosis: A target for gene therapy. Kidney Int 1997; 51: 1388-96.
11. Duman S, Gunal AI, Sen S, Aşçi G, Özkahya M, Terzioǧlu E, Akçiçek F, Atabay G. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21: 219-24.
12. Gunal AI, Duman S, Sen S, Ünsal A, Terzioǧlu E, Aki̧çek F, Bşçi A. By reducing TGF β1, octreotide lessens the peritoneal derangements induced by high glucose solution. J Nephrol 2001; 14: 184-89.
13. Günal AI,Çeliker H, Akpolat N, Üstündaǧ B, Duman S, Akçiçek F. Reducing the production of VEGF, octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution. Perit Dial Int 2002; 22: 301-6.
14. Fried LF, Orchard TJ, Kasiske BL for the Lipids and Renal Disease Progression Meta-Analysis Study Group. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001; 59: 260-9.
15. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in the rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62: 367-74.
16. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988; 33: 667-72.
17. Galle J, Heinloth A, Wanner C, Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through oxidative stress. Kidney Int 2001; 78 (suppl): S120-3.
18. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-7.
19. Yoshimura A, Nemoto T, Sugenoya Y, Inui K, Watanabe S, Inoue Y, Sharif S, Yokota N, Uda S, Morita H, Ideura T. Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int 1999; 56 (suppl 71): S84-7.
20. Nishimura M, Tanaka T, Yasuda T, Kurakata S, Kitagawa M, Yamada K, Saito Y, Hirai A. Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation. Kidney Int 1999; 56 (suppl 71): S97-100.
21. Nogaki F, Muso E, Yashiro M, Kasuno K, Kamata T, Ono T, Sasayama S. Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells. Kidney Int 1999; 56 (suppl 71): S198-201.
22. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11: 863-9.
23. Marumo H, Satoh K, Yamamoto A. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakuhaku Zasshi 2001; 121: 761-4.
24. S. Sen, Duman S, Başçi A, Akçiçek F, Atabay G. Parietal peritoneal morphology with different fixatives in experimental studies (abstract). Perit Dial Int 2002; 22: 152.
25. Duman S, Sen S, Günal AI, Akçiçek F, Başçi A. How can we standartise peritoneal thickness measurement in experimental studies in rats? Perit Dial Int 2001; 21 (suppl 3): S338-41.
26. Garosi G, Di Paolo N. Morphological aspects of peritoneal sclerosis. J Nephrol 2001; 14: (suppl 4): S30-8.
27. Hung KY, Tsai TJ, Chen WY. Peritoneal fibrosis and its prevention. Nephrology 2002; 7: 227-32.
28. AI-Jayyousi RH, Medcalf JM, Harris K PG. Role of transforming growth factor beta in peritoneal fibrosis. Nephrology 2002; 7: 227-32.
29. Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19: 180-5.
30. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, Westenfeld R, Floege J, Rippe B. Biocompatibility of peritoneal dialysis fluids: Long-term exposure of nonuremic rats. Perit Dial Int 2004; 24: 37-47.
31. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon K. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-β1 of human peritoneal mesothelial cells: Effect of cytokine costimulation. Perit Dial Int 1999; 19: 221-30.
32. Kumano K, Schiller-Moran B, Hjelle JT, Moran JE. Effect of high glucose levels on cell proliferation and TGF- β expression in cultured rat mesothelial cell (abstract). J Am Soc Nephrol 1993; 4: 410.
33. Nakamura S, Niwa T. Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol 2004; 24: 502-5.
34. Massy ZA, Guijarro C. Statins: Effects beyond cholesterol lowering. Nephrol Dial Transplant 2001, 16: 1738-41.
35. Asberg A, Hartman A, Fjeldsa E, Holdas H. Atorvastatin improves endothelial function in renal transplant recipients. Nephrol Dial Transplant 2001; 16: 1920-4.
36. Kumar S, Thuraisingham RC, Raftery MJ, Fan SL, Yaqoob MM. Statins have anti-inflammatory effects in continious ambulatory peritoneal dialysis patients (abstract). J Am Soc Nephrol 2003; 14: 737.
37. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 24; 104: 376-9.
38. Dechend R, Müller D, Park JK, Fiebeler A, Haller H. Statins and angiotensin II-induced vascular injury. Nephrol Dial Transplant 2002; 17: 349-53.